Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Equity Average: 2013-2025

Historic Equity Average for Ascendis Pharma A (ASND) over the last 11 years, with Sep 2025 value amounting to -$105.5 million.

  • Ascendis Pharma A's Equity Average rose 53.40% to -$105.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.5 million, marking a year-over-year increase of 53.40%. This contributed to the annual value of -$135.6 million for FY2024, which is 342.29% down from last year.
  • Per Ascendis Pharma A's latest filing, its Equity Average stood at -$105.5 million for Q3 2025, which was up 48.79% from -$206.0 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Equity Average ranged from a high of $1.1 billion in Q4 2021 and a low of -$226.4 million during Q3 2024.
  • Its 3-year average for Equity Average is -$98.0 million, with a median of -$109.9 million in 2024.
  • As far as peak fluctuations go, Ascendis Pharma A's Equity Average soared by 224.56% in 2021, and later tumbled by 193,565.45% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Equity Average (Quarterly) stood at $1.1 billion in 2021, then tumbled by 87.68% to $134.4 million in 2022, then slumped by 188.05% to -$118.3 million in 2023, then rose by 7.12% to -$109.9 million in 2024, then surged by 53.40% to -$105.5 million in 2025.
  • Its Equity Average was -$105.5 million in Q3 2025, compared to -$206.0 million in Q2 2025 and -$156.3 million in Q1 2025.